Skip to content
LXEOLexeo Therapeutics, Inc.

Earnings

When Lexeo Therapeutics, Inc. reports, what it reported each quarter, and how the stock took the results.

19 quarters. Mar 31, 2022 to Sep 30, 2026. USD.

Next results · Q4 2026Projected

Mar 29, before the open

Mon, Mar 29, 2027in 132 days

Projected from its last 8 releases. The company has not named the day yet.

Quarter
Q4 2026 · Ends about Dec 31, 2026
10-K window
Mar 5 – Apr 6

Read against Q4 2025

The same quarter a year earlier, the figures the next ones will be compared with. Thaler holds no estimates.

Revenue
—
Net income
-$20.96M
Net income, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q4 2025 n/m
EPS
—
EPS, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q3 2025 n/m

Quarter by quarter

Q4 2023—

Latest results

  1. Q3 2026Nov 16, 2026, before the openThe release
    Revenue
    —
    —
    Net income
    -$38.30M
    N/M
    EPS
    -$0.43
    N/M
    In the press release described in Item 2.02 above, the Company announced positive interim Phase I/II clinical data and regulatory updates for LX2020 for the treatment of PKP2-associated arrhythmogenic cardiomyopathy (“ PKP2-ACM ”).
  2. Q2 2026Aug 12, 2026, before the openThe release+1.7%by the close of Aug 12
    Revenue
    —
    —
    Net income
    -$25.87M
    N/M
    EPS
    -$0.30
    N/M
  3. Q1 2026May 11, 2026, before the openThe release+5.2%by the close of May 11
    Revenue
    —
    —
    Net income
    -$20.20M
    N/M
    EPS
    -$0.25
    N/M
  4. Q4 2025Mar 30, 2026, after the closeThe release+9.3%by the close of Mar 31
    Revenue
    —
    —
    Net income
    -$20.96M
    N/M
    EPS
    —
    —

All quarters

PeriodEndedAnnouncedFiledLagFormRevenueΔ yoyEPS dil.MoveSource trail
FY 2026
Q3 2026Sep 30, 2026Nov 16, 2026 · pre-marketNov 16, 202647 d10-Q——-$0.43—
Q2 2026Jun 30, 2026Aug 12, 2026 · pre-marketAug 12, 202643 d10-Q——-$0.30+1.7%
Q1 2026Mar 31, 2026May 11, 2026 · pre-marketMay 11, 202641 d10-Q——-$0.25+5.2%
FY 2025
Q4 2025derivedDec 31, 2025Mar 30, 2026 · after-hoursMar 30, 202689 d10-K———+9.3%
Q3 2025Sep 30, 2025Nov 5, 2025 · pre-marketNov 5, 202536 d10-Q——-$0.332.0%
Q2 2025Jun 30, 2025Aug 14, 2025 · pre-marketAug 14, 202545 d10-Q——-$0.600.2%
Q1 2025Mar 31, 2025May 12, 2025 · pre-marketMay 12, 202542 d10-Q——-$0.991.9%
FY 2024
Q4 2024derivedDec 31, 2024Mar 24, 2025 · pre-marketMar 24, 202583 d10-K———+51.2%
Q3 2024Sep 30, 2024Nov 13, 2024 · pre-marketNov 13, 202444 d10-Q——-$0.89+0.3%
Q2 2024Jun 30, 2024Aug 12, 2024 · pre-marketAug 12, 202443 d10-Q——-$0.64+4.2%
Q1 2024Mar 31, 2024May 9, 2024 · pre-marketMay 9, 202439 d10-Q——-$0.77—
Earlier years, FY 2022 to FY 2023

Move: the stock from the last close before the release to the first close after it. Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Source filings

10-QNov 16, 2026462020
10-QAug 12, 2026345724
10-QMay 11, 2026215678
10-KMar 30, 2026132085
10-QNov 5, 2025265757
10-QAug 14, 2025108427
10-QMay 12, 2025068536
10-KMar 24, 2025043486
10-QNov 13, 2024125943
10-QAug 12, 2024095057

Provenance

ProvenanceData status and checks

Lexeo Therapeutics, Inc. · CIK 1907108 · Engraved from SEC EDGAR